ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

摘要:

Protease inhibitors are a key component of the new era of AIDS treatment. Treating patients with HIV infection with a protease inhibitor in addition to 1 or 2 nucleoside analogues leads to dramatic reductions in viral load. This has been demonstrated in a study of saquinavir, zidovudine and lamivudine. A trial investigating the clinical effects of saquinavir + zalcitabine has also shown that dual therapy prolongs survival in this patient group, compared with either drug alone. Another important development is the use of 2 protease inhibitors to treat HIV infection. Preliminary data from a study of saquinavir [F Hoffmann-La Roche] + ritonavir [Abbott] have shown that this well-tolerated combination leads to profound viral suppression. These studies were presented at the 11th International Conference on AIDS [Vancouver, Canada; July 1996].

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

摘要:

In addition to standardising quality in drug use and assisting in the management of medical outcomes, appropriate-use programmes can reduce overall treatment costs, according to speakers at a Zeneca-sponsored symposium held during the 1996 Annual Meeting of the American Society of Health-System Pharmacists [San Diego, US; June 1996]. Appropriate-use programmes have become increasingly important in the US following the introduction of integrated healthcare and managed-care systems. In this report,Inpharma® describes the development of a successfully implemented appropriate-use programme, and takes a look at a number of areas that may be suitable for this type of intervention.

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

摘要:

Sumatriptan has been the gold standard of migraine treatment since its launch 5 years ago. However, it accounts for only 8.5% of all migraine therapy prescriptions worldwide. The drug is not an option for some patients due to its high cost. For others, it is ineffective or unacceptable in available formulations. Further to this, sumatriptan will soon face competition from a number of new serotonin agonists that are reaching the final stages of development. The latest data on these competitors were presented at the 3rd European Headache Conference [Sardinia; June 1996].

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1996

数据来源: ADIS